$ILMN

Leckman Patricia sold $47K of ILMN

Leckman Patricia (SVP, Chief People Officer) sold 290 shares of ILLUMINA, INC. (ILMN) at $163.02 on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Leckman Patricia
Published Jun 4, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Neutral
high confidence
Mentioned
$ILMN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider activity but does not indicate a new operational or financial catalyst for Illumina.

02

Market read

Primarily sentiment/positioning noise; no fundamental reset implied by the filing alone.

03

What to watch

The sale size is modest relative to typical institutional float; without additional context (other insider trades, guidance, or operational news), signal is limited.

Relevance 6/10Novelty 2/10Timing: Filed after-hours/late day (2026-06-04) for a June 2 sale.

Background

SEC Form 4 reports insider transactions (officers/directors/10% owners). This one is an open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$ILMNNeutralHigh confidence
Context

Illumina disclosed an open-market sale by SVP/Chief People Officer Patricia Leckman under a pre-arranged 10b5-1 plan on June 2.

Expected impact

Low near-term impact; any reaction is likely limited to intraday sentiment/positioning rather than a trend change.

Evidence & confidence

The filing is a routine Form 4 insider transaction and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

No clear read-through to genomics/sequencing peers from a single routine 10b5-1 Form 4.

None.

None.

Counterpoint

Even 10b5-1 sales can coincide with internal expectations; traders may watch for a clustering of insider sales around specific dates.

Key entities

  • Illumina, Inc.

    Company whose shares were sold by an officer under a 10b5-1 plan.

  • Patricia Leckman

    SVP, Chief People Officer who sold 290 shares on 2026-06-02.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNHighAI 8/10

Illumina Q2FY26 Results: Revenue up 9.5% to $1.16 billion

Illumina reported Q2 2026 revenue of $1.16B, up 9.5% YoY, driven by NovaSeq X demand and clinical consumables growth. Non-GAAP EPS rose 10% to $1.31. The company raised full-year guidance, projecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40. Management cited strong instrument placements and cost management despite rising expenses. Illumina repurchased 0.9M shares and holds $1.17B in cash. The stock has returned 13.26% annually over 20 years, outperforming the market by 3.84%.

$ILMNHighAI 8/10

Illumina Reports Q2 2026 Results: Full Earnings Call Transcript - Illumina (NASDAQ:ILMN)

Illumina (ILMN) reported Q2 2026 revenue growth of 9.5% YoY and EPS growth of 10%, driven by strong demand for NovaSeq X. The company raised its 2026 guidance, expecting full-year organic revenue growth over 5% and mid-teens growth in clinical consumables. Strategic initiatives include expanding multi-omics capabilities and strengthening the BioInsight platform. Management emphasized cost management and confidence in long-term targets.

$BELow

Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns?

Vanguard S&P 500 ETF (VOO) will add Bloom Energy (BE), Illumina (ILMN), and another company, while removing Molson Coors (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR). BE's product revenue surged 215% due to AI demand, and ILMN raised EPS guidance. The changes have minimal impact on VOO's returns, as the fund is heavily concentrated in megacap stocks.

$ILMNHigh

Illumina Stock Climbs As Analyst Upgrades Meet S&P 500 Boost

Illumina Inc. (ILMN) shares rose 7.15% on September 15, 2026, after UBS upgraded it to Buy with a $260 price target, and Argus raised its target to $235. The company's Q2 revenue was $1.16B, with EBITDA of $354M. Illumina is also being added to the S&P 500, effective September 21, 2026, which may drive further demand. The stock trades at a P/E ratio of 38 and P/S ratio of 6.9, reflecting its growth prospects. Analysts cite revenue reacceleration, margin expansion, and clinical demand as key driv